03 Jan 2012
(MENAFN) Gulf Pharmaceutical Industries (Julphar) said that commercial output of insulin at the firm’s new factory in Ras Al Khaimah (RAK) would be expected to start in 2012’s first quarter, reported The National.
The firm added that the USD136.1 million plant, which the company began to establish in the summer, has an annual output capacity of producing more than 50 million vials of insulin.
It also said that the firm would reduce the cost of insulin to the increasing number of diabetics in the region by manufacturing the drug locally, pointing out that nearly 90 percent of pharmaceuticals in the UAE are imported.
It is worth noting that Julphar’s sales in 2011 surpassed USD272.2, with total revenues up 11.3 percent to USD278 million.
04 Aug 2025
HM the King’s Support for Youth is an Inspirational Model for Their Empowerment Journey
28 Jul 2025
BBK discloses its financial results for the half year ended 30th June 2025
20 Jul 2025
CBB approves the transfer of the retail banking operations of HSBC Bank Middle East, Bahrain Branch to BBK
08 Jul 2025
BBK proudly launches the third edition of “Grow” and welcomes 20 Bahraini graduates
03 Jul 2025
BBK hosts executive leadership session on digital assets in collaboration with Rain
02 Jul 2025
BBK launches the largest-ever Al Hayrat Prizes, offering BD 5 million to over 2,000 winners
16 Jun 2025
BBK and CrediMax Offer Exclusive 20% Discount on Turkish Airlines Flights for Cardholders
25 May 2025
BBK strengthens commitment to sports development through strategic partnership with Bahrain Basketball Association
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more